Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Hair loss is a common but often unreported side effect of cancer treatments, especially for breast and prostate cancers.

Hair loss is a common side effect of hormone treatments for cancer.

In this study, researchers assessed the efficacy of Trichosera® hair serum, containing mesenchymal stromal cells conditioned media, among 40 healthy Indian volunteers, finding significant improvements in hair growth rate, hair density, scalp condition, and reduction in hair fall without notable adverse effects.

This article discusses challenges and limitations of using simple tissue mechanics for repairing head and neck skin defects in trauma and does not report new findings; it highlights potential problems with routine methods.

This study carried out a detailed pharmacognostic and phytochemical analysis of Sphagneticola calendulacea leaves, which may help authenticate this plant used in treating inflammation and alopecia.

In this study, beagle dogs treated with hydrocortisone 17-butyrate 21-propionate ointment showed various toxic effects, including acne-like skin changes and organ atrophy, which returned to normal after a recovery period.

This article reviews the reported sexual and psychological side effects of 5-alpha reductase inhibitors for benign prostatic hyperplasia, emphasizing the need for further clinical studies.

In this study, short-term treatment with lovastatin showed no effect on symptom severity, prostate volume, or PSA levels in men with prostatic enlargement from presumed benign prostatic hyperplasia.

This article reviews the impact of aging and related urologic conditions on male fertility, highlighting the effects of various treatments on sperm parameters and recommending pre-treatment counseling for fertility preservation. It reports no new clinical results.

This study concluded that finasteride is a viable first-line treatment for moderate uncomplicated benign prostatic hyperplasia, particularly in patients with larger prostates, by significantly reducing acute urinary retention and the need for surgery.

This review discusses the negative health impacts of testosterone deficiency and the potential adverse effects of 5α-reductase inhibitors, emphasizing the need for patient-physician discussions regarding these treatments.

This review discusses the role of the TOR pathway in aging and suggests that rapamycin could potentially target age-related diseases, but reports no new clinical results.

Finasteride helps regrow hair and shrink prostate by reducing DHT, with some sexual side effects.

This review discusses the properties and therapeutic potentials of beta-sitosterol, highlighting a need for more detailed studies on its mechanisms and long-term effects in humans; it reports no new results.

In this study, Ganoderma lucidum extract was found to significantly inhibit 5alpha-reductase activity and testosterone-induced prostate growth in rats, suggesting potential use for treating benign prostatic hyperplasia.

This review discusses the clinical and molecular history of 5-alpha reductase deficiency, highlighting its role in male sexual differentiation and potential therapeutic applications, but reports no new research outcomes.

This case report suggests a possible association between long-term finasteride use for male pattern baldness and the development of cataracts and intraoperative floppy-iris syndrome in a patient.

In this study, there was no evidence that using 5α-reductase inhibitors for either short or long durations increased the risk of male breast cancer.

This study reported a significant increase in the reporting of sexual dysfunction associated with finasteride use, especially in individuals aged 31-45.

This review discusses persistent sexual and nonsexual adverse effects of the 5α-reductase inhibitor finasteride in younger men, including erectile dysfunction, low libido, and depression. It reports no new clinical results but emphasizes further research is needed.

This review explores the potential impact of hormonal changes during aging on benign prostate hyperplasia-related urinary symptoms and metabolic syndrome, highlighting the hypothesis of a male PCOS-equivalent but reports no new clinical results.

This review discusses the potential uses of 5α-reductase inhibitors for conditions ranging from benign prostatic hyperplasia to skin disorders like acne and male pattern baldness, but it reports no new clinical results.

This study found that the optimized finasteride-loaded lyophilized tablets using a self-nanoemulsifying drug delivery system improved bioavailability in human volunteers compared to the marketed finasteride product.

This article discusses advancements and future directions in the treatment of benign prostatic hyperplasia, highlighting ongoing clinical trials of novel techniques, but it reports no new clinical results.

This study found that the phytosterols β-sitosterol, stigmasterol, and campesterol have low-to-negligible inhibitory activity against steroidal 5α-reductase type 2 compared to the synthetic inhibitor dutasteride, with β-sitosterol showing the highest activity among the tested phytosterols.

This study identified ten novel compounds that may effectively target steroid 5 alpha-reductase 2 (5αR-2) for potential treatment of benign prostate hyperplasia, exhibiting comparable binding energies to existing drugs like finasteride and dutasteride.

This review discusses post-finasteride syndrome, emphasizing its serious psychological and cognitive symptoms and the need for more research and awareness in the medical community, but provides no new clinical findings.

This study found that LHE may prevent and reverse testosterone-induced prostatic hyperplasia, supporting the traditional use of Kigelia africana for some reproductive system disorders.

This review discusses the occurrence of persistent sexual, physical, neurological, and psychiatric side effects known as post-finasteride syndrome after 5x-reductase inhibitor treatment, and emphasizes the importance of evaluating these risks for patients with benign prostatic hyperplasia or androgenic alopecia.

This study found that combining finasteride and anastrozole was more effective in preventing and treating benign prostatic hyperplasia in rats than using either drug alone.